Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Exablate 4000 Clear all
Recruiting Early Phase 1 Interventional

Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma

NCT07076472
View directory record Official record
Conditions
Progressive Glioblastoma, Recurrent Glioblastoma
Interventions
Aminolevulinic Acid Intravenous Formulation SONALA-001, Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, MRI-Guided Focused Ultrasound Ablation, Oral Aminolevulinic Acid Hydrochloride
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 2, 2026, 10:12 PM EDT
Active, not recruiting Not applicable Interventional

Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)

NCT04728295
View directory record Official record
Conditions
Parkinson Disease
Interventions
Exablate 4000
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
6
States / cities
Palo Alto, California • Delray Beach, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Sep 2, 2026, 10:12 PM EDT
Active, not recruiting Early Phase 1 Interventional

Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy

NCT05469009
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease 1
Interventions
Aducanumab, Exablate Model 4000 Type 2, Lecanemab
Drug · Device
Lead sponsor
Ali Rezai
Other
Eligibility
50 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 2, 2026, 10:12 PM EDT
Recruiting No phase listed Observational

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications

NCT05539196
View directory record Official record
Conditions
Movement Disorders, Neurology, Parkinsons Disease
Interventions
Exablate Pallidotomy, Unilateral
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 2, 2026, 10:12 PM EDT
Active, not recruiting Phase 1 Interventional

The Impact of Focused Ultrasound Thalamotomy of the Anterior Nucleus for Focal-Onset Epilepsy on Anxiety

NCT05032105
View directory record Official record
Conditions
Anxiety, Medication-refractory Focal-onset Epilepsy
Interventions
Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA)
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 2, 2026, 10:12 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)

NCT04197921
View directory record Official record
Conditions
Opioid-use Disorder, Substance Use Disorders
Interventions
Exablate Model 4000 Type 2.0/2.1
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
4
States / cities
Tampa, Florida • Baltimore, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 2, 2026, 10:12 PM EDT
Recruiting Not applicable Interventional

Extracellular Impact of Ultrasound-induced Blood-brain Barrier Disruption

NCT05733312
View directory record Official record
Conditions
Brain Tumor
Interventions
InSightec's ExAblate Neuro Model 4000 Type 2.0 (220 KHz) system
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 2, 2026, 10:12 PM EDT
Suspended Phase 2 Interventional

A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG

NCT05123534
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma
Interventions
SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
Combination Product
Lead sponsor
SonALAsense, Inc.
Industry
Eligibility
5 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
San Francisco, California • Washington D.C., District of Columbia • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 2, 2026, 10:12 PM EDT
Recruiting Not applicable Interventional

ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

NCT03671889
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Blood Brain Barrier (BBB) Disruption
Device
Lead sponsor
InSightec
Industry
Eligibility
50 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
10
States / cities
Delray Beach, Florida • Fort Lauderdale, Florida • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 2, 2026, 10:12 PM EDT
Active, not recruiting Not applicable Interventional

A Pilot Study: Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset Epilepsy

NCT03417297
View directory record Official record
Conditions
Partial Seizures With Secondary Generalization, Focal Epilepsy With Secondary Generalization
Interventions
High Intensity Focused Ultrasound
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 2, 2026, 10:12 PM EDT
Active, not recruiting Not applicable Interventional

Bilateral Treatment of Medication Refractory Essential Tremor

NCT04112381
View directory record Official record
Conditions
Essential Tremor
Interventions
Exablate Model 4000 Type 1.0/1.1
Device
Lead sponsor
InSightec
Industry
Eligibility
22 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Stanford, California • Baltimore, Maryland • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 2, 2026, 10:12 PM EDT
Active, not recruiting No phase listed Observational

Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders:

NCT03100474
View directory record Official record
Conditions
Essential Tremor, Parkinson's Disease, Movement Disorders, Neuropathic Pain
Interventions
Not listed
Lead sponsor
InSightec
Industry
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Stanford, California • Baltimore, Maryland • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 2, 2026, 10:12 PM EDT
Suspended Not applicable Interventional

ExAblate Blood Brain Barrier Disruption (BBBD) for Planned Surgery in Suspected Infiltrating Glioma

NCT03322813
View directory record Official record
Conditions
Glioma
Interventions
ExAblate 4000 - Type 2
Device
Lead sponsor
InSightec
Industry
Eligibility
21 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 2, 2026, 10:12 PM EDT
Withdrawn Not applicable Interventional

Safety and Effectiveness of Blood-Brain Barrier Disruption (BBBD) in Subjects With Suspected Infiltrating Glioma

NCT04667715
View directory record Official record
Conditions
Glioma
Interventions
Exablate BBBD
Device
Lead sponsor
InSightec
Industry
Eligibility
21 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 2, 2026, 10:12 PM EDT
Completed Not applicable Interventional

Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors

NCT05383872
View directory record Official record
Conditions
Glioblastoma, Glioma, Liquid Biopsy
Interventions
Focused Ultrasound (Exablate Model 4000)
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 80 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
16
States / cities
Los Angeles, California • Newport Beach, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 2, 2026, 10:12 PM EDT
Completed Not applicable Interventional

Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption

NCT03551249
View directory record Official record
Conditions
Glioma, Glioblastoma
Interventions
Focused ultrasound (FUS)
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Charlottesville, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 2, 2026, 10:12 PM EDT
Recruiting No phase listed Observational

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease

NCT04991831
View directory record Official record
Conditions
Tremor Associated With Tremor Dominant Parkinson's Disease
Interventions
Unilateral thalamotomy
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 2, 2026, 10:12 PM EDT
Completed Not applicable Interventional

Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD)

NCT06612788
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Exablate Model 4000 Type 2.0/2.1
Device
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 2, 2026, 10:12 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM

NCT05370508
View directory record Official record
Conditions
Recurrent GBM
Interventions
SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
Combination Product
Lead sponsor
SonALAsense, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Phoenix, Arizona • San Francisco, California • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Sep 2, 2026, 10:12 PM EDT
Recruiting Phase 3 Interventional

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

NCT05317858
View directory record Official record
Conditions
Brain Tumor, Non Small Cell Lung Cancer
Interventions
Blood Brain Barrier Opening - Oncology, Pembrolizumab, Atezolizumab, Cemiplimab, Nivolumab, Iptilimumab
Device · Drug
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Phoenix, Arizona • Newport Beach, California • Fort Lauderdale, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 10:12 PM EDT
Recruiting Not applicable Interventional

A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects

NCT03028246
View directory record Official record
Conditions
Benign Centrally-Located Intracranial Tumors
Interventions
ExAblate 4000 System
Device
Lead sponsor
InSightec
Industry
Eligibility
5 Years to 22 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Miami, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 2, 2026, 10:12 PM EDT